Levosimendan Kabi (Levosimendan)

Levosimendan sensitises troponin C to calcium, which enhances myocardial contractile force without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering afterload, together supporting overall cardiac output.

The dose of Levosimendan Kabi is determined by the prescribing clinician based on the patient’s clinical status, severity of heart failure, blood pressure, and response to therapy. Specific dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Levosimendan Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative for inotropic support in acute heart failure is dobutamine, a beta‑adrenergic agonist. Unlike dobutamine, levosimendan increases contractility without raising intracellular calcium and also provides vasodilation, which may result in a more favorable hemodynamic profile and longer duration of action after infusion.

Levosimendan Kabi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use, and allow it to reach room temperature only briefly if required for preparation under aseptic conditions.

Levosimendan Kabi is administered intravenously, typically as a continuous infusion under medical supervision. The infusion is prepared in a sterile diluent and delivered via an infusion pump, allowing precise control of the rate and duration as directed by the treating physician.

The most serious risks include severe hypotension, which can compromise organ perfusion, ventricular arrhythmias that may be life‑threatening, and myocardial ischemia due to increased cardiac work. Patients should be closely monitored for these events throughout the infusion period.

Levosimendan Kabi is contraindicated in patients with known hypersensitivity to the drug, those experiencing severe hypotension, recent myocardial infarction, or uncontrolled arrhythmias. Caution is also advised in individuals with significant renal or hepatic impairment, and the decision to treat should be made by a qualified clinician.